HRP20200529T1 - Postupci i pripravci za modificiranje ciljnog lokusa - Google Patents

Postupci i pripravci za modificiranje ciljnog lokusa Download PDF

Info

Publication number
HRP20200529T1
HRP20200529T1 HRP20200529TT HRP20200529T HRP20200529T1 HR P20200529 T1 HRP20200529 T1 HR P20200529T1 HR P20200529T T HRP20200529T T HR P20200529TT HR P20200529 T HRP20200529 T HR P20200529T HR P20200529 T1 HRP20200529 T1 HR P20200529T1
Authority
HR
Croatia
Prior art keywords
cell
polynucleotide
nucleic acid
nuclease
acid sequence
Prior art date
Application number
HRP20200529TT
Other languages
English (en)
Inventor
Wojtek Auerbach
David Frendewey
Gustavo Droguett
Anthony Gagliardi
Junko Kuno
David M. Valenzuela
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of HRP20200529T1 publication Critical patent/HRP20200529T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Environmental Sciences (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (18)

1. Postupak za serijsku modifikaciju ciljnog lokusa u ćeliji, naznačen time što sadrži: (a) osiguravanje ćelije koja sadrži ciljni lokus, pri čemu ciljni lokus sadrži polinukleotid koji kodira prvi selekcijski marker koji je operativno povezan sa prvim promotorom i koji sadrži prvo mjesto za prepoznavanje za prvo sredstvo nukleaze, pri čemu je prvo mjesto za prepoznavanje nukleaze smješteno u kodirajućoj regiji prvog selekcijskog markera ili bilo kojoj ne-protein-kodirajućoj regiji prvog selekcijskog markera, izborno pri čemu je ciljni lokus u genomu ćelije ili je smješten u vektoru u ćeliji; (b) uvođenje u ćeliju: (i) prvog sredstva nukleaze, pri čemu prvo sredstvo nukleaze izaziva zarez ili dvolančani prekid na prvom mjestu za prepoznavanje nukleaze, čime se narušava ekspresija ili aktivnost prvog selekcijskog markera; i (ii) prvog vektora koji ciljno djeluje koji sadrži prvi umetnuti polinukleotid omeđen sa bočnih strana prvom homolognom granom koja odgovara prvom ciljnom mjestu smještenom u ciljnom lokusu i drugom homolognom granom koja odgovara drugom ciljnom mjestu smještenom u ciljnom lokusu, pri čemu prvi umetnuti polinukleotid sadrži: (I) prvi polinukleotid od interesa; i (II) polinukleotid koji kodira drugi selekcijski marker koji je operativno povezan sa drugim promotorom i koji sadrži drugo mjesto za prepoznavanje nukleaze za drugo sredstvo nukleaze, pri čemu su prvi selekcijski marker i drugi selekcijski marker različiti, pri čemu je prvo sredstvo nukleaze različito od drugog sredstva nukleaze, i pri čemu je drugo mjesto za prepoznavanje nukleaze smješteno u kodirajućoj regiji drugog selekcijskog markera ili bilo kojoj ne-protein-kodirajućoj regiji drugog selekcijskog markera; (c) identificiranje modificirane ćelije koja sadrži prvi umetnuti polinukleotid na ciljnom lokusu, pri čemu modificirana ćelija ima aktivnost drugog selekcijskog markera, ali nema aktivnost prvog selekcijskog markera, izborno pri čemu se identificiranje vrši putem testa modifikacije alela (MOA); (d) uvođenje u modificiranu ćeliju: (i) drugog sredstva nukleaze, pri čemu drugo sredstvo nukleaze izaziva zarez ili dvolančani prekid na drugom mjestu za prepoznavanje nukleaze, čime se narušava ekspresija ili aktivnost drugog selekcijskog markera; i (ii) drugog vektora koji ciljno djeluje koji sadrži drugi umetnuti polinukleotid omeđen sa bočnih strana trećom homolognom granom koja odgovara trećem ciljnom mjestu smještenom u ciljnom lokusu i četvrtom homolognom granom koja odgovara četvrtom ciljnom mjestu smještenom u ciljnom lokusu, pri čemu drugi umetnuti polinukleotid sadrži: (I) drugi polinukleotid od interesa; i (II) polinukleotid koji kodira treći selekcijski marker koji je operativno povezan sa trećim promotorom koji je aktivan u ćeliji i koji sadrži treće mjesto za prepoznavanje nukleaze za treće sredstvo nukleaze, pri čemu su prvi selekcijski marker i treći selekcijski marker identični, i pri čemu je treće mjesto za prepoznavanje nukleaze identično prvom mjestu za prepoznavanje nukleaze i različito je od drugog mjesta za prepoznavanje nukleaze, i prvo sredstvo nukleaze i treće sredstvo nukleaze identični su jedno drugome i različiti su od drugog sredstva nukleaze; i (e) identificiranje najmanje jedne ćelije koja sadrži drugi umetnuti polinukleotid integriran u ciljni lokus, izborno pri čemu se identificiranje vrši putem testa modifikacije alela (MOA).
2. Postupak prema patentnom zahtjevu 1, naznačen time što korak identificiranja (c) sadrži: (i) uzgajanje ćelije pod uvjetima koji omogućavaju identificiranje ćelija koje nemaju aktivnost prvog selekcijskog markera; ili (ii) identificiranje najmanje jedne ćelije koja sadrži prvi umetnuti polinukleotid integriran u prvo i drugo ciljno mjesto; i/ili pri čemu korak identificiranja (e) sadrži: (i) uzgajanje ćelije pod uvjetima koji omogućavaju identificiranje ćelija koje nemaju aktivnost drugog selekcijskog markera; ili (ii) identificiranje najmanje jedne ćelije koja sadrži drugi umetnuti polinukleotid integriran u treće i četvrto ciljno mjesto.
3. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što je polinukleotid koji kodira drugi selekcijski marker u modificiranoj ćeliji u koraku (c) omeđen sa bočnih strana trećim ciljnim mjestom i četvrtim ciljnim mjestom.
4. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što prvi, drugi, ili treći selekcijski marker daje rezistenciju na antibiotik, izborno pri čemu antibiotik sadrži G418, higromicin, blasticidin, neomicin, ili puromicin, ili pri čemu je prvi, drugi, ili treći selekcijski marker operativno povezan sa inducibilnim promotorom, i ekspresija selekcijskog markera je toksična za ćeliju, izborno pri čemu prvi, drugi, ili treći selekcijski marker sadrži hipoksantin-guanin fosforiboziltransferazu (HGPRT) ili timidin kinazu Herpes simplex virusa (HSV-TK).
5. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što je ćelija eukariotska ćelija, izborno pri čemu je eukariotska ćelija ćelija sisavca, izborno pri čemu je ćelija sisavca: (a) ćelija ne-ljudskog sisavca; (b) pluripotentna ćelija; (c) ljudski izazvana pluripotentna matična ćelija; (d) ljudski fibroblast; ili (e) ćelija glodavca.
6. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što je ćelija embrionalna matična (ES) ćelija miša ili ES ćelija štakora.
7. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što kombinirana uporaba prvog vektora koji ciljno djeluje sa prvim sredstvom nukleaze rezultira povećanom efikasnošću ciljnog djelovanja u usporedbi sa uporabom samo prvog vektora koji ciljno djeluje, izborno pri čemu je efikasnost ciljnog djelovanja prvog vektora koji ciljno djeluje povećana najmanje dvostruko u usporedbi sa uporabom samo prvog vektora koji ciljno djeluje.
8. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što prvo sredstvo nukleaze, drugo sredstvo nukleaze, ili treće sredstvo nukleaze: (a) sadrži polinukleotid koji kodira sredstvo nukleaze, pri čemu je polinukleotid sadržan u kaseti ekspresije i operativno je povezan sa kondicionalnim promotorom, inducibilnim promotorom, konstitutivnim promotorom, ili tkivno-specifičnim promotorom; (b) je iRNK koja kodira nukleazu; (c) je cinčani prst nukleaze (ZFN); (d) je efektorska nukleaza slična aktivatoru transkripcije (TALEN); (e) je meganukleaza; ili (f) je okupljena kratkim palindromskim ponavljanjima na jednakim razmacima (CRISPR)-povezan (Cas) protein i vodeća RNK (gRNA).
9. Postupak prema patentnom zahtjevu 8, naznačen time što je prvo sredstvo nukleaze, drugo sredstvo nukleaze, ili treće sredstvo nukleaze Cas protein i vodeća RNK, pri čemu je Cas protein Cas9, i pri čemu vodeća RNK (gRNA) sadrži: (a) CRISPR RNK (crRNA) koja cilja prvo, drugo, ili treće mjesto za prepoznavanje, pri čemu je prvo, drugo, ili treće mjesto za prepoznavanje neposredno omeđeno sa bočnih strana protorazmaknice susjednog motiva (PAM) sekvencom. (b) trans-aktivirajuću CRISPR RNK (tracrRNA); izborno pri čemu ciljni lokus sadrži nukleotidnu sekvencu SEQ ID NO: 1; i izborno pri čemu gRNA sadrži himernu RNK koja ima sekvencu nukleinske kiseline SEQ ID NO: 2 ili SEQ ID NO: 3 ili tracrRNA koja sadrži SEQ ID NO: 7 ili SEQ ID NO: 8.
10. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što: (a) prvo ciljno mjesto i drugo ciljno mjesto su neposredno pored prvog mjesta za prepoznavanje nukleaze; (b) prvo ciljno mjesto i drugo ciljno mjesto su oko 10 nukleotida do oko 14 kb od prvog mjesta za prepoznavanje nukleaze; (c) treće ciljno mjesto i četvrto ciljno mjesto su neposredno pored drugog mjesta za prepoznavanje nukleaze; ili (d) treće ciljno mjesto i četvrto ciljno mjesto su oko 10 nukleotida do oko 14 kb od drugog mjesta za prepoznavanje nukleaze.
11. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što: (a) ukupan zbroj prve homologne grane i druge homologne grane je najmanje oko 10 kb ili je svaka od prve i druge homologne grane u opsegu od oko 5 kb do oko 100 kb; i/ili (b) ukupan zbroj treće homologne grane i četvrte homologne grane je najmanje oko 10 kb ili je svaka od treće i četvrte homologne grane u opsegu od oko 5 kb do oko 100 kb; i/ili (c) prvi vektor koji ciljno djeluje je najmanje oko 10 kb ili je od oko 20 kb do oko 300 kb; i/ili (d) drugi vektor koji ciljno djeluje je najmanje oko 10 kb ili je od oko 20 kb do oko 300 kb; i/ili (e) prvi umetnuti polinukleotid dugačak je u opsegu od oko 5 kb do oko 300 kb; i/ili (f) drugi umetnuti polinukleotid dugačak je u opsegu od oko 5 kb do oko 300 kb.
12. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što: (a) integracija prvog umetnutog polinukleotida u ciljni lokus rezultira knockout-om, knock-in-om, točkastom mutacijom, zamjenom domena, zamjenom egzona, zamjenom introna, zamjenom regulatorne sekvence, zamjenom gena, ili njihovom kombinacijom; i/ili (b) integracija drugog umetnutog polinukleotida u ciljni lokus rezultira knockout-om, knock-in-om, točkastom mutacijom, zamjenom domena, zamjenom egzona, zamjenom introna, zamjenom regulatorne sekvence, zamjenom gena, ili njihovom kombinacijom.
13. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što: (a) prvi polinukleotid od interesa sadrži ljudski polinukleotid, sekvencu nukleinske kiseline koja je homologna ili ortologna sekvenci nukleinske kiseline u genomu ćelije, ili sekvencu egzogene nukleinske kiseline, izborno pri čemu prvi polinukleotid od interesa sadrži: (i) regiju alfa lokusa T ćelijskog receptora, izborno pri čemu prvi polinukleotid od interesa sadrži najmanje jedan segment gena varijabilne regije i/ili segment gena povezujuće regije alfa lokusa T ćelijskog receptora; ili (ii) nereorganizranu sekvencu nukleinske kiseline varijabilne regije teškog lanca ljudskog imunoglobulina koja je operativno povezana sa sekvencom nukleinske kiseline konstantne regije teškog lanca imunoglobulina; i/ili (b) drugi polinukleotid od interesa sadrži ljudski polinukleotid, sekvencu nukleinske kiseline koja je homologna ili ortologna sekvenci nukleinske kiseline u genomu ćelije, ili sekvencu egzogene nukleinske kiseline, izborno pri čemu drugi polinukleotid od interesa sadrži: (i) regiju alfa lokusa T ćelijskog receptora, izborno pri čemu drugi polinukleotid od interesa sadrži najmanje jedan segment gena varijabilne regije i/ili segment gena povezujuće regije alfa lokusa T ćelijskog receptora; ili (ii) nereorganiziranu sekvencu nukleinske kiseline varijabilne regije teškog lanca ljudskog imunoglobulina koja je operativno povezana sa sekvencom nukleinske kiseline konstantne regije teškog lanca imunoglobulina.
14. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što: (a) prvi polinukleotid od interesa i/ili drugi polinukleotid od interesa sadrži najmanje jedan alel bolesti; (b) prvi polinukleotid od interesa i/ili drugi polinukleotid od interesa sadrži sekvencu genske nukleinske kiseline koja kodira amino-kiselinsku sekvencu varijabilne regije teškog lanca ljudskog imunoglobulina; ili (c) prvi polinukleotid od interesa i/ili drugi polinukleotid od interesa sadrži sekvencu genske nukleinske kiseline koja kodira amino-kiselinsku sekvencu varijabilne regije lakog lanca ljudskog imunoglobulina, izborno pri čemu: (i) sekvenca genske nukleinske kiseline sadrži nereorganiziranu sekvencu nukleinske kiseline varijabilne regije λ i/ili κ lakog lanca; ili (ii) sekvenca genske nukleinske kiseline sadrži reorganiziranu sekvencu nukleinske kiseline varijabilne regije λ i/ili κ lakog lanca.
15. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što: (a) ciljni lokus sadrži lokus imunoglobulina; ili (b) ciljni lokus sadrži lokus T ćelijskog receptora, izborno pri čemu je lokus T ćelijskog receptora alfa lokus T ćelijskog receptora.
16. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što prvo sredstvo nukleaze, drugo sredstvo nukleaze, i treće sredstvo nukleaze su svaki Cas protein i vodeća RNK, i pri čemu je vodeća RNK (gRNA) specifična za gen za rezistenciju na higromicin ili neomicin.
17. Postupak prema patentnom zahtjevu 16, naznačen time što je gRNA specifična za gen za rezistenciju na neomicin kodirana nukleinskom kiselinom koja sadrži nukleotidnu sekvencu iznijetu u SEQ ID NO: 13, 14, 15, ili 16, ili pri čemu je gRNA specifična za gen za rezistenciju na higromicin kodirana nukleinskom kiselinom koja sadrži nukleotidnu sekvencu iznijetu u SEQ ID NO: 17, 18, 19, ili 20.
18. Postupak prema patentnom zahtjevu 17, naznačen time što: (a) prva gRNA kodirana je nukleinskom kiselinom koja sadrži nukleotidnu sekvencu iznijetu u SEQ ID NO: 13, 14, 15, ili 16, i druga gRNA kodirana je nukleinskom kiselinom koja sadrži nukleotidnu sekvencu iznijetu u SEQ ID NO: 17, 18, 19, ili 20; ili (b) prva gRNA kodirana je nukleinskom kiselinom koja sadrži nukleotidnu sekvencu iznijetu u SEQ ID NO: 17, 18, 19, ili 20, i druga gRNA kodirana je nukleinskom kiselinom koja sadrži nukleotidnu sekvencu iznijetu u SEQ ID NO: 13, 14, 15, ili 16.
HRP20200529TT 2014-06-06 2015-06-05 Postupci i pripravci za modificiranje ciljnog lokusa HRP20200529T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462008832P 2014-06-06 2014-06-06
US201462017916P 2014-06-27 2014-06-27
EP15729724.3A EP3152312B1 (en) 2014-06-06 2015-06-05 Methods and compositions for modifying a targeted locus
PCT/US2015/034503 WO2015188109A1 (en) 2014-06-06 2015-06-05 Methods and compositions for modifying a targeted locus

Publications (1)

Publication Number Publication Date
HRP20200529T1 true HRP20200529T1 (hr) 2020-09-04

Family

ID=53404960

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200529TT HRP20200529T1 (hr) 2014-06-06 2015-06-05 Postupci i pripravci za modificiranje ciljnog lokusa

Country Status (25)

Country Link
US (4) US10106820B2 (hr)
EP (2) EP3152312B1 (hr)
JP (2) JP6688231B2 (hr)
KR (1) KR102374379B1 (hr)
CN (2) CN113215196B (hr)
AU (1) AU2015269187B2 (hr)
BR (1) BR112016028564A2 (hr)
CA (1) CA2950173C (hr)
CY (1) CY1122897T1 (hr)
DK (1) DK3152312T3 (hr)
ES (2) ES3019688T3 (hr)
HR (1) HRP20200529T1 (hr)
HU (1) HUE049776T2 (hr)
IL (1) IL249042B (hr)
LT (1) LT3152312T (hr)
MX (1) MX385689B (hr)
NZ (1) NZ727481A (hr)
PL (1) PL3152312T3 (hr)
PT (1) PT3152312T (hr)
RS (1) RS60359B1 (hr)
RU (1) RU2704283C9 (hr)
SG (2) SG11201609634YA (hr)
SI (1) SI3152312T1 (hr)
SM (1) SMT202000264T1 (hr)
WO (1) WO2015188109A1 (hr)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
CN104364380B (zh) 2012-04-25 2018-10-09 瑞泽恩制药公司 核酸酶介导的使用大靶向载体的靶向
AU2014218931C1 (en) 2013-02-20 2020-05-14 Regeneron Pharmaceuticals, Inc. Genetic modification of rats
CA2908697C (en) 2013-04-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
SG10201700961TA (en) 2013-12-11 2017-04-27 Regeneron Pharma Methods and compositions for the targeted modification of a genome
HUE041331T2 (hu) 2013-12-11 2019-05-28 Regeneron Pharma Módszerek és készítmények a genom célzott módosításához
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
HUE049776T2 (hu) 2014-06-06 2020-10-28 Regeneron Pharma Módszerek és készítmények egy célzott lókusz módosítására
EP3161128B1 (en) 2014-06-26 2018-09-26 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modifications and methods of use
CA2956224A1 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
DK3207124T3 (da) 2014-10-15 2019-08-12 Regeneron Pharma Fremgangsmåder og sammensætninger til generering eller bevaring af pluripotente celler
EP3221457B1 (en) 2014-11-21 2019-03-20 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide rnas
JP6840077B2 (ja) 2014-12-19 2021-03-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 単一ステップの複数標的化を通じた標的化された遺伝子修飾のための方法及び組成物
DK3359660T3 (en) 2015-10-05 2020-02-17 Prec Biosciences Inc Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
DK3359184T3 (da) * 2015-10-05 2020-06-15 Prec Biosciences Inc Genetisk modificerede celler, der omfatter et modificeret gen fra konstant alfaregion i human t-cellereceptor
EP4434589A3 (en) 2015-10-23 2025-05-14 President and Fellows of Harvard College Evolved cas9 proteins for gene editing
RU2018135819A (ru) * 2016-03-11 2020-04-13 Блубёрд Био, Инк. Иммунные эффекторные клетки с отредактированным геномом
US11802281B2 (en) * 2016-04-04 2023-10-31 Eth Zurich Mammalian cell line for protein production and library generation
SG11201808831TA (en) 2016-04-15 2018-11-29 Memorial Sloan Kettering Cancer Center Transgenic t cell and chimeric antigen receptor t cell compositions and related methods
CN109475109B (zh) * 2016-05-20 2021-10-29 瑞泽恩制药公司 用于使用多个引导rna来破坏免疫耐受性的方法
SI3462853T1 (sl) 2016-06-03 2023-05-31 Regeneron Pharmaceuticals, Inc. Glodavci, ki izražajo eksogeno terminalno deoksinukleotidiltransferazo
CN107513538A (zh) * 2016-06-17 2017-12-26 北京大学 基因敲除方法
US11359234B2 (en) 2016-07-01 2022-06-14 Microsoft Technology Licensing, Llc Barcoding sequences for identification of gene expression
US20180004537A1 (en) 2016-07-01 2018-01-04 Microsoft Technology Licensing, Llc Molecular State Machines
WO2018005117A1 (en) 2016-07-01 2018-01-04 Microsoft Technology Licensing, Llc Storage through iterative dna editing
JP7231935B2 (ja) 2016-08-03 2023-03-08 プレジデント アンド フェローズ オブ ハーバード カレッジ アデノシン核酸塩基編集因子およびそれらの使用
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
AU2017342543B2 (en) 2016-10-14 2024-06-27 President And Fellows Of Harvard College AAV delivery of nucleobase editors
EP3766343B1 (en) 2016-11-04 2022-05-11 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
SG10202109874VA (en) 2017-01-19 2021-10-28 Open Monoclonal Tech Inc Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
WO2018151514A1 (ko) * 2017-02-16 2018-08-23 고려대학교 산학협력단 골재생 효능이 우수한 골질환 예방 또는 치료용 조성물
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
WO2018167621A1 (en) * 2017-03-16 2018-09-20 Pfizer Inc. Tyrosine prototrophy
WO2018176009A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
CA3068465A1 (en) 2017-06-30 2019-01-03 Precision Biosciences, Inc. Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
EP3652320B1 (en) 2017-07-12 2025-12-24 Mayo Foundation for Medical Education and Research Materials and methods for efficient targeted knock in or gene replacement
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US12012596B2 (en) * 2017-08-21 2024-06-18 Tokushima University Target sequence specific alteration technology using nucleotide target recognition
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
JP2020534812A (ja) * 2017-09-08 2020-12-03 ライフ テクノロジーズ コーポレイション 改良された相同組換えおよびその組成物のための方法
KR20200121782A (ko) 2017-10-16 2020-10-26 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US20210017544A1 (en) * 2017-12-22 2021-01-21 Novozymes A/S Counter-Selection by Inhibition of Conditionally Essential Genes
CN107904208B (zh) * 2017-12-25 2019-11-01 云舟生物科技（广州）有限公司 细胞表型研究用的细胞克隆及其筛选方法和应用
CN111742051A (zh) * 2018-01-23 2020-10-02 基础科学研究院 延伸的单向导rna及其用途
US20190256867A1 (en) 2018-02-01 2019-08-22 Homology Medicines, Inc. Adeno-associated virus compositions for restoring pah gene function and methods of use thereof
JP7328243B2 (ja) 2018-03-26 2023-08-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療薬を試験するためのヒト化げっ歯類
US11786554B2 (en) 2018-04-12 2023-10-17 Precision Biosciences, Inc. Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene
TW202014519A (zh) * 2018-05-04 2020-04-16 美商羅卡斯生物科學公司 殺目標細菌之組合物及方法
CN112654710A (zh) 2018-05-16 2021-04-13 辛瑟高公司 用于指导rna设计和使用的方法和系统
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
CN117904208A (zh) * 2018-12-30 2024-04-19 豪夫迈·罗氏有限公司 基于可检测标签与靶蛋白的CRISPR/Cas控制的整合而选择细胞的方法
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
US11111504B2 (en) * 2019-04-04 2021-09-07 Regeneron Pharmaceuticals, Inc. Methods for scarless introduction of targeted modifications into targeting vectors
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
WO2020232081A2 (en) * 2019-05-13 2020-11-19 Rapid Genomics Llc Capture and analysis of target genomic regions
WO2021016608A1 (en) * 2019-07-25 2021-01-28 Precision Biosciences, Inc. Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2021119594A1 (en) * 2019-12-13 2021-06-17 The Regents Of The University Of California Reducing antibiotic resistance in bacteria using pro-active genetics
IL271656A (en) 2019-12-22 2021-06-30 Yeda Res & Dev System and methods for identifying cells that have undergone genome editing
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
US20240018493A1 (en) * 2020-11-10 2024-01-18 The Board Of Trustees Of The Leland Stanford Junior University Knock-in of large dna for long-term high genomic expression
CN114763559B (zh) * 2021-01-15 2024-07-19 中国农业大学 一种不依赖于同源重组的靶向性基因捕获系统及其应用
WO2023046038A1 (en) * 2021-09-24 2023-03-30 Immunocan Biotech Co. Ltd. Methods for large-size chromosomal transfer and modified chromosomes and organisims using same
EP4709869A1 (en) * 2023-05-10 2026-03-18 Takeda Pharmaceutical Company Limited Re-editable templates, cells, compositions and methods of making

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992003917A1 (en) 1990-08-29 1992-03-19 Genpharm International Homologous recombination in mammalian cells
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
AU8587598A (en) 1997-07-26 1999-02-16 Wisconsin Alumni Research Foundation Trans-species nuclear transfer
DK1015576T3 (da) * 1997-09-16 2005-08-29 Egea Biosciences Llc Fremgangsmåde til fuldstændig kemisk syntese og aggregering af gener og genomer
WO2000039316A1 (en) 1998-12-31 2000-07-06 The J. David Gladstone Institutes Transgenic rodents and rodent cell lines expressing hiv co-receptors
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
CA2394850C (en) 1999-12-06 2012-02-07 Sangamo Biosciences, Inc. Methods of using randomized libraries of zinc finger proteins for the identification of gene function
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
EP1341914A2 (en) 2000-12-07 2003-09-10 Sangamo Biosciences Inc. Regulation of angiogenesis with zinc finger proteins
AU2002225187A1 (en) 2001-01-22 2002-07-30 Sangamo Biosciences, Inc. Zinc finger polypeptides and their use
DK1353941T3 (da) 2001-01-22 2013-06-17 Sangamo Biosciences Inc Modificerede zinkfingerbindingsproteiner
AUPR451401A0 (en) 2001-04-20 2001-05-24 Monash University A method of nuclear transfer
US20030082591A1 (en) 2001-07-24 2003-05-01 Donald Awrey Methods for gene disruption and uses thereof
ATE347593T1 (de) 2002-01-23 2006-12-15 Univ Utah Res Found Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
US8206965B2 (en) 2002-03-15 2012-06-26 Cellectis S.A. Hybrid and single chain meganucleases and use thereof
EP1504092B2 (en) 2002-03-21 2014-06-25 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US7612250B2 (en) 2002-07-29 2009-11-03 Trustees Of Tufts College Nuclear transfer embryo formation method
WO2004037977A2 (en) 2002-09-05 2004-05-06 California Institute Of Thechnology Use of chimeric nucleases to stimulate gene targeting
AU2003290518A1 (en) 2002-09-06 2004-04-23 Fred Hutchinson Cancer Research Center Methods and compositions concerning designed highly-specific nucleic acid binding proteins
US20030175968A1 (en) 2002-10-30 2003-09-18 Golic Kent G. Gene targeting method
CA2513226A1 (en) 2003-01-13 2004-07-29 Mahendra S. Rao Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP1591521A1 (en) 2004-04-30 2005-11-02 Cellectis I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof
AU2005287278B2 (en) 2004-09-16 2011-08-04 Sangamo Biosciences, Inc. Compositions and methods for protein production
AU2005295269B2 (en) 2004-10-19 2010-05-13 Regeneron Pharmaceuticals, Inc. Method for generating an animal homozygous for a genetic modification
FR2879622B1 (fr) 2004-12-17 2008-02-01 Agronomique Inst Nat Rech Procede in vitro de production d'ovocytes ou d'oeufs presentant une modification genomique ciblee
ES2347684T3 (es) 2005-03-15 2010-11-03 Cellectis Variantes de la meganucleasa i-crei con especificidad modifica, metodo de preparacion y usos de las mismas.
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
WO2007005053A1 (en) 2005-06-30 2007-01-11 Codon Devices, Inc. Hierarchical assembly methods for genome engineering
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
CN101117633B (zh) 2006-08-03 2011-07-20 上海交通大学附属儿童医院 一种细胞核移植方法
US9187758B2 (en) 2006-12-14 2015-11-17 Sangamo Biosciences, Inc. Optimized non-canonical zinc finger proteins
US7771967B2 (en) 2006-12-22 2010-08-10 The J. David Gladstone Institutes Nucleic acid encoding apolipoprotein E-I3
US8110379B2 (en) 2007-04-26 2012-02-07 Sangamo Biosciences, Inc. Targeted integration into the PPP1R12C locus
KR102096731B1 (ko) 2007-06-01 2020-04-02 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
KR20100103810A (ko) 2007-12-10 2010-09-28 알리바 바이오파마수티컬스, 아이엔씨. 동종 재조합에 의한 표적화된 영역의 순차적인 치환 방법
JP5681114B2 (ja) 2008-12-04 2015-03-04 サンガモ バイオサイエンシーズ， インコーポレイテッド 亜鉛フィンガーヌクレアーゼを使用したラットのゲノム編集
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
AU2010226313B2 (en) 2009-03-20 2014-10-09 Sangamo Therapeutics, Inc. Modification of CXCR4 using engineered zinc finger proteins
EP2425018A4 (en) 2009-04-30 2013-06-05 Univ Columbia IN VIVO CONSTRUCTION OF DNA BY HOMOLOGOUS RECOMBINATION
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
CN102638971B (zh) * 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
US20120178647A1 (en) 2009-08-03 2012-07-12 The General Hospital Corporation Engineering of zinc finger arrays by context-dependent assembly
WO2011051390A1 (en) 2009-10-28 2011-05-05 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Homologous recombination in the oocyte
WO2011059799A1 (en) 2009-10-29 2011-05-19 Regeneron Pharmaceuticals, Inc. Multifunctional alleles
US20120315670A1 (en) 2009-11-02 2012-12-13 Gen9, Inc. Compositions and Methods for the Regulation of Multiple Genes of Interest in a Cell
EP2508595B1 (en) 2009-12-01 2016-11-23 National Cancer Center Method for constructing chimeric rat using rat embryonic stem cells
EP3456826B1 (en) 2009-12-10 2023-06-28 Regents of the University of Minnesota Tal effector-mediated dna modification
CA2951341A1 (en) 2009-12-21 2011-06-30 Keygene N.V. Improved techniques for transfecting protoplasts
GEP201606544B (en) 2010-01-22 2016-09-26 Dow Agrosciences Llc Excision of transgenes in genetically modified organisms
EP2534163B1 (en) 2010-02-09 2015-11-04 Sangamo BioSciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
GB201009732D0 (en) 2010-06-10 2010-07-21 Gene Bridges Gmbh Direct cloning
CA2800534C (en) 2010-06-11 2019-01-22 Regeneron Pharmaceuticals, Inc. Production of fertile xy female animals from xy es cells
AU2011266843C9 (en) * 2010-06-17 2018-03-01 Kymab Limited Animal models and therapeutic molecules
CA2993567C (en) 2010-07-21 2022-06-28 Sangamo Biosciences, Inc. Methods and compositions for modification of a t-cell receptor gene
WO2012018726A1 (en) 2010-08-02 2012-02-09 Cellectis Sa Method for increasing double-strand break-induced gene targeting
WO2012129198A1 (en) 2011-03-23 2012-09-27 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for obesity and diabetes
CN114891797A (zh) 2011-10-28 2022-08-12 瑞泽恩制药公司 T细胞受体基因修饰小鼠
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
CN104364380B (zh) * 2012-04-25 2018-10-09 瑞泽恩制药公司 核酸酶介导的使用大靶向载体的靶向
CA2871524C (en) 2012-05-07 2021-07-27 Sangamo Biosciences, Inc. Methods and compositions for nuclease-mediated targeted integration of transgenes
PL4289948T3 (pl) 2012-05-25 2025-06-02 The Regents Of The University Of California Sposoby i kompozycje do modyfikacji kierowanego na rna docelowego dna i do nakierowanej na rna modulacji transkrypcji
EP2912175B1 (en) 2012-10-23 2018-08-22 Toolgen Incorporated Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
CN105142669B (zh) 2012-12-06 2018-07-03 西格马-奥尔德里奇有限责任公司 基于crispr的基因组修饰和调控
WO2014093622A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
PT2898075E (pt) 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições de enzima melhorados para manipulação de sequências
CN105658796B (zh) * 2012-12-12 2021-10-26 布罗德研究所有限公司 用于序列操纵的crispr-cas组分系统、方法以及组合物
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
EP4282970A3 (en) 2012-12-17 2024-01-17 President and Fellows of Harvard College Rna-guided human genome engineering
DK2938184T3 (en) 2012-12-27 2018-12-17 Keygene Nv Method of removing a genetic linkage in a plant
AU2014218931C1 (en) 2013-02-20 2020-05-14 Regeneron Pharmaceuticals, Inc. Genetic modification of rats
EP2922393B2 (en) 2013-02-27 2022-12-28 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Gene editing in the oocyte by cas9 nucleases
WO2014143381A1 (en) 2013-03-09 2014-09-18 Agilent Technologies, Inc. Methods of in vivo engineering of large sequences using multiple crispr/cas selections of recombineering events
US20140349400A1 (en) 2013-03-15 2014-11-27 Massachusetts Institute Of Technology Programmable Modification of DNA
US9234213B2 (en) * 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
WO2014153470A2 (en) * 2013-03-21 2014-09-25 Sangamo Biosciences, Inc. Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
JP2016522679A (ja) 2013-04-04 2016-08-04 プレジデント アンド フェローズ オブ ハーバード カレッジ ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
CA2908697C (en) 2013-04-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Targeted modification of rat genome
CN116083487A (zh) 2013-05-15 2023-05-09 桑格摩生物治疗股份有限公司 用于治疗遗传病状的方法和组合物
JP7065564B2 (ja) 2013-05-29 2022-05-12 セレクティス Ｃａｓ９ニッカーゼ活性を用いて正確なｄｎａ切断をもたらすための方法
AU2014281472A1 (en) 2013-06-19 2016-01-21 Sigma-Aldrich Co. Llc. Targeted integration
EP3418379B1 (en) 2013-09-18 2020-12-09 Kymab Limited Methods, cells & organisms
WO2015052231A2 (en) 2013-10-08 2015-04-16 Technical University Of Denmark Multiplex editing system
US10787684B2 (en) 2013-11-19 2020-09-29 President And Fellows Of Harvard College Large gene excision and insertion
SG10201700961TA (en) 2013-12-11 2017-04-27 Regeneron Pharma Methods and compositions for the targeted modification of a genome
WO2015086798A2 (en) 2013-12-13 2015-06-18 Cellectis New method of selection of algal-transformed cells using nuclease
US10233456B2 (en) 2014-01-30 2019-03-19 The Board Of Trustees Of The University Of Arkansas Method, vectors, cells, seeds and kits for stacking genes into a single genomic site
US20170076039A1 (en) 2014-04-24 2017-03-16 Institute For Basic Science A Method of Selecting a Nuclease Target Sequence for Gene Knockout Based on Microhomology
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
HUE049776T2 (hu) 2014-06-06 2020-10-28 Regeneron Pharma Módszerek és készítmények egy célzott lókusz módosítására
EP3161128B1 (en) 2014-06-26 2018-09-26 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modifications and methods of use
DK3207124T3 (da) 2014-10-15 2019-08-12 Regeneron Pharma Fremgangsmåder og sammensætninger til generering eller bevaring af pluripotente celler
EP3221457B1 (en) 2014-11-21 2019-03-20 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide rnas
JP6840077B2 (ja) 2014-12-19 2021-03-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 単一ステップの複数標的化を通じた標的化された遺伝子修飾のための方法及び組成物
GB201504223D0 (en) 2015-03-12 2015-04-29 Genome Res Ltd Biallelic genetic modification
WO2019046350A1 (en) 2017-08-30 2019-03-07 President And Fellows Of Harvard College ITERATIVE GENOMIC ASSEMBLY

Also Published As

Publication number Publication date
CA2950173C (en) 2023-10-10
ES2784754T3 (es) 2020-09-30
RU2704283C2 (ru) 2019-10-25
US20190225992A1 (en) 2019-07-25
RU2016150168A (ru) 2018-07-18
AU2015269187A1 (en) 2017-01-12
IL249042A0 (en) 2017-01-31
PT3152312T (pt) 2020-04-23
EP3708671A1 (en) 2020-09-16
ES3019688T3 (en) 2025-05-21
JP2020137521A (ja) 2020-09-03
US10106820B2 (en) 2018-10-23
NZ727481A (en) 2023-06-30
SMT202000264T1 (it) 2020-07-08
PL3152312T3 (pl) 2020-08-10
SG10201913804WA (en) 2020-03-30
US20170211099A1 (en) 2017-07-27
CN106795521A (zh) 2017-05-31
CY1122897T1 (el) 2021-05-05
EP3152312B1 (en) 2020-02-12
SI3152312T1 (sl) 2020-07-31
EP3152312A1 (en) 2017-04-12
IL249042B (en) 2021-09-30
AU2015269187B2 (en) 2021-06-17
RU2016150168A3 (hr) 2018-12-05
JP2017520243A (ja) 2017-07-27
CN113215196A (zh) 2021-08-06
US10294494B2 (en) 2019-05-21
CN113215196B (zh) 2024-09-03
US20240352489A1 (en) 2024-10-24
US12060571B2 (en) 2024-08-13
KR102374379B1 (ko) 2022-03-17
DK3152312T3 (da) 2020-04-06
WO2015188109A1 (en) 2015-12-10
CA2950173A1 (en) 2015-12-10
LT3152312T (lt) 2020-04-27
BR112016028564A2 (pt) 2018-01-30
CN106795521B (zh) 2021-06-04
US20150376650A1 (en) 2015-12-31
RU2704283C9 (ru) 2020-02-07
RS60359B1 (sr) 2020-07-31
JP6688231B2 (ja) 2020-04-28
AU2015269187A2 (en) 2017-01-19
EP3708671C0 (en) 2025-04-02
SG11201609634YA (en) 2016-12-29
MX2016016133A (es) 2017-08-04
HUE049776T2 (hu) 2020-10-28
KR20170027743A (ko) 2017-03-10
MX385689B (es) 2025-03-18
JP7154248B2 (ja) 2022-10-17
EP3708671B1 (en) 2025-04-02

Similar Documents

Publication Publication Date Title
HRP20200529T1 (hr) Postupci i pripravci za modificiranje ciljnog lokusa
AU2021290301B2 (en) METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION USING PAIRED GUIDE RNAs
US10301646B2 (en) Nuclease-mediated targeting with large targeting vectors
JP6840077B2 (ja) 単一ステップの複数標的化を通じた標的化された遺伝子修飾のための方法及び組成物
HK40035693A (en) Methods and compositions for modifying a targeted locus
HK1235817B (en) Methods and compositions for modifying a targeted locus
HK1235817A1 (en) Methods and compositions for modifying a targeted locus
RU2019132992A (ru) Способы и композиции для модификации целевого локуса
HK1207396B (en) Nuclease-mediated targeting with large targeting vectors